AstraZeneca vaccine as third dose effective against Omicron: Study
PTI, Jan 13, 2022, 4:00 PM IST
Image for representation
London: The AstraZeneca Vaxzevaria vaccine showed an increased antibody response to the Omicron variant of COVID-19 after a third booster dose, preliminary data released by the Anglo-Swedish biopharma major said on Thursday.
In an ongoing safety and immunogenicity trial of the vaccine, a formulation developed by Oxford University and administered in India as Covishield, it was found that given as a third dose increased the body’s immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
A separate analysis of samples from the trial showed increased antibody response to the Omicron variant. The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine.
The company said it is submitting this additional data to health authorities around the world given the urgent need for third dose boosters.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
10 month baby gets new heart, new life
World COPD Day: Know your lung function
As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all
World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness
World Diabetes Day: An overview of types of diabetes
MUST WATCH
Latest Additions
SC notice to Gujarat govt on Asaram’s plea seeking suspension of sentence in 2013 rape case
BJP stages protest against Karnataka govt over Waqf properties row
US charges against Adani, 7 others could lead to arrest warrants, extradition bid: attorney
Youth attempts suicide after being humiliated in public for wearing ripped jeans in Belthangady
Baku climate talks: The ‘X’ factor that could determine future of Global South
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.